Correction: Kikuchi, K., et al., Potential of the Angiotensin Receptor Blockers (ARBs) Telmisartan, Irbesartan, and Candesartan for Inhibiting the HMGB1/RAGE Axis in Prevention and Acute Treatment of Stroke. Int. J. Mol. Sci. 2013, 14, 18899–18924

Correction: Kikuchi, K., et al., Potential of the Angiotensin Receptor Blockers (ARBs) Telmisartan, Irbesartan, and Candesartan for Inhibiting the HMGB1/RAGE Axis in Prevention and Acute Treatment of Stroke. Int. J. Mol. Sci. 2013, 14, 18899–18924

The original version of the paper [1] reports that "This ACTIVE I study was supported by Pfizer" (Page 18905). However, the sponsors of the ACTIVE I study were actually Bristol-Myers Squibb and Sanofi-Aventis rather than Pfizer. [...]

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of molecular sciences 2014-03, Vol.15 (4), p.5410-5411
Hauptverfasser: Kikuchi, Kiyoshi, Tancharoen, Salunya, Ito, Takashi, Morimoto-Yamashita, Yoko, Miura, Naoki, Kawahara, Ko-ichi, Maruyama, Ikuro, Murai, Yoshinaka, Tanaka, Eiichiro
Format: Artikel
Sprache:eng
Schlagworte:
n/a
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The original version of the paper [1] reports that "This ACTIVE I study was supported by Pfizer" (Page 18905). However, the sponsors of the ACTIVE I study were actually Bristol-Myers Squibb and Sanofi-Aventis rather than Pfizer. [...]
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms15045410